{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"66.5","upperLimit":"86.1","value":"76.3"},{"groupId":"OG001","lowerLimit":"94.8","upperLimit":"99.8","value":"97.3"},{"groupId":"OG002","lowerLimit":"85.1","upperLimit":"98.9","value":"92.0"},{"groupId":"OG003","lowerLimit":"95.0","upperLimit":"100.0","value":"98.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"64"},{"groupId":"OG003","value":"63"}],"units":"Participants"}],"description":"OS was defined as the time interval from date of study entry to date of death from any cause or to date of last contact for survivors. OS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% CI's.","dispersionType":"95% Confidence Interval","groups":[{"description":"Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and classified as Group 3 medulloblastoma by methylation arrays","id":"OG000","title":"Group 3 Medulloblastoma"},{"description":"Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and classified as Group 4 medulloblastoma by methylation arrays","id":"OG001","title":"Group 4 Medulloblastoma"},{"description":"Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and classified as SHH medulloblastoma by methylation arrays","id":"OG002","title":"Sonic Hedgehog (SHH) Medulloblastoma"},{"description":"Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and classified as WNT medulloblastoma by methylation arrays","id":"OG003","title":"Wingless (WNT) Medulloblastoma"}],"paramType":"NUMBER","populationDescription":"355 patients were classified into one of the medulloblastoma subgroups by methylation arrays and included in this analysis; 74 were Group 3 medulloblastoma, 154 were Group 4 medulloblastoma, 64 were SHH medulloblastoma, and 63 were WNT medulloblastoma patients.","reportingStatus":"POSTED","timeFrame":"3 years","title":"Overall Survival (OS) by Molecular Subgroup Based on Methylation Arrays","type":"SECONDARY","unitOfMeasure":"Percent probability of overall survival"}